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Abstracr The main objective ofthis work is to model and debotileneck a phannaceutical
production of an anti-allergic cream. The base cas€ process has a rninimum cycle time of
i9 hours which is equivalent to 66 batchestear. Four schemes were proposed for
proc$s debottlenecking due to the anticipated increase ofthe product demand of 150%
in the ma*et. By carrying out throughp$ analysis study, sohemes that ftlfil the
debottlenecking objective were determined. Out of the four debottleneoking schemes,
Scheme 4 was choseq which proposed a new blending tank and intermediare ftnk,
showed aproducrion i crease ofover 150%.
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I. ]NTRODUCTION
Computer Aided Prooess Design (CAPD) and
simulation tools have been widely used in the bulk
and petrochemical industries since the early 1960's.
It involves the use of computers to perform steady_
stat€ h€at and mass balancing a! well as lizing a:nd
costing calcularions for a process {We$erberg er a/.
1979). However the use of these CAPD and
simulation tools has only emerged in the
pharmaceutical ma.ufacturing in the past decade
(Petrides, et ,1, 195; Hwa4, 1997; Emst et aI.,
1997; Koulouris, er al, 20OOt Petides, et al , ZO0Za,
b; Ol\ et al., 2004). Colnpared to tbe readily
availabl€ comnercial process simulato$ in lhe bulk
and lerochemical industries, lhere are only a limited
number of commercial simulators available for
pharmaceutical process modelling in the market,
*hich include Batches by Batch Process
Technolosies, Barch Plus by Aspen Technolo8v,
SuperPro Designer by l elligen as well as Batch
Design Kit by Hyproteoh. This situation is mainly
due ro the oonstraints associated with the nodelling
of pharmaceutical processes, which include the
mcomlnon unit operatrons and batlb operation natwe
of phamaoeutical prooessing. Due to its relatively
new emergenoe, much work needs to b€ done in ihis
This pap€r describes the use ofthe commercial batch
proc€ss simulator SuperPro Designer v5.0 in tb€
modelling and debohlenecking of an anli-allergic
creain production line at a local phamaceutioal
faciliry. Due to the increasing customer demand of
th€ anti-allergic cream product, the pharnaceutical
facilit management t€am is looking for a.ltemative
expansion sohemes lo iDcrease the curent production
raie as the Foduction oapacitj is limited by the
cunent operaling oondition and e4uipment setuP.
Hence, a debottleneoking study is needed for an
increas€ in production.
2. BACKGROUND THEORY
ln order to jnoease the prooess throughput the
proc€ss bottleneck that limits the curreDt pJoducrion
need to be identified. Bottlenecks de process
limitations fta1 are related to eith€r equipmeDt or
resource such as deinand for various utilities, labour,
rav materiat, etc. H€nc€, proc€ss debottletecking
can b€ defined a! the identifcation and removal of
obstacles in the attempt to increase the plant
throughput (Koulouh, et at, 2000). In batch
marufeturing, two types of process bottl€n€cks can
be oategorised. These are the equipm€nt capacrty'
related size bottlenerk (an equipmett tlut is limited in
siz€) as well as th€ scheduling bottleneck (due to the
long occupancy of an equipmenl during a Process)
Tle abilit to identiS and remove process
bottlenecks that create obstacles in a nanufaoturing
process will increase plant throughput and tulfrl
A good roolro identiry bath p.oces5 bonleneck is via
a throughput aralysis study. Thrcughput analysis
measures the equipment utilisation in a batch process
with two variables, i.e. the capacity utilisation and
equipment uptime (Koulouris, €t dl, 2000; Petrides,
et al.,2002a). Capac;iy utilisadon is defmed as the
percerlage of the curent operaling load of an
equipment relative to its itaximum load On the other
hand, equipme uprime neasures $e effectivetess of
a piece of equipnent that is utilised iD lime lt is
given as tle p€rcentage of the equ;pnent utilisarion
time over th€ plant cycle time Tle Prodlct of
equipment capaoit utilisation and its uptine defines
the combined utilisation of the respective quipment
(Koulouris, er at , 2000; P etides, et al., 2002a)- 'the
processing step with the highest combined utilisation
is identified as the process bottleneck. Simulatton




of process bottlenecks and the development of the
soenaiios for process debottlene.king. By using the
"what if' scenario, prooess altematives can be
sinulated via the use of simulation tools to reveal
potential cand;dates for lhe debonlenecting srud)
3. MODEL DEVELOPMENT
Fig. I shows the base case simulatio' flowsheet for
th€ production of anriallergic cream modelled in
SuperPro Design€r v5.0. Du€ to the nature of the
process that is operated in batch mode, tbe base case
simulation model was developed to rcflect tbe actual
operating condition of the cutrent production i, the
existing pharmaceutioal manufacturing facili9.
Fig. 1. Base case simuladon flowsheet for lhe
production of anti'allergic oream
ln Lhe baqe case process. rhere are nine major
processing sleps in three diferent sub-sections This
includes raw material melting in the Pre-mix'ng
Section, Main Blending Section, as well as filling,
cartoning, pekaging (shrink wrapping) and shipment
packaging in the Pa.kaging sectio.s. Fifty ttto
operation weeks were taken as the basis of this work.
Tuo barches of emuhibins wax 
'LSw) and rom
stabiliser (FS) are independently heated in the beati.g
procedures P-l (oarried out in Jacketed Heate.V-101)
and P-2 (in Jackered Heater V-102) to approximately
100'c b€fore the ernulsifier GMUL) and ointnent
rOIN) are added.
D€ionised rDn water is heated in the electric heater
EH-101 (procedure P-3) before beins transfened rnto
the Main Blending Tank, V-103 (P-4) in the Main
Blending Section. An antirnicrobial agent (AM) h
n€xt added into the hot DI water. The mixtore in the
jacketei heater V-101 and V-102 is then tansfened
into V-103 and all insredients in V-103 are blended
for a uniform composition. The mixture is then lefr in
an air-conditioned dispensing foon to be narurally
cooled to room temperature. This cooling operation
took approxnnately 19 hours to accomplish due to the
slow rate of natual cooling. Upon the completion of
the cooling ope.atio., the active ingredient (AI) ofthe
antiallereic crean is finaliy added before rhe produot
mixture is sent ro the PackagiDg Section.
ln the Packaging Seotion, the anti all€rgic cream is
filled into tbe tubes of 15 g eaoh. The existing filling
nachine is operated ar a speed of 30 tubevmin. The
tubes are then s€nt 10 the canoning packaging
procedure P-? (using a belt conveyer P-6/tsC-101)
where the anti-allersic oream in tubes are paoked
malually by two operators into the tube cartons, each
at a speed of 20 cartons/min. Next, 12 oartons of
anti-allergic cream are packed into one wrapper in the
skink wrapper (P-8/CBX-101), with a speed of 5
lvrapp€r/min. Finally, 6 wrappen are packed tnto
each of the pallet boxes in P-9|BX-102 (equivalent o
72 tubes/pallet box) before they are sent to the
warchouse. Approximately 6 sealed pallet boxes are
packed per minute by the operator manually.
As the manufacturing process is carried out in a batch
operation, efforts have be€n mad€ to document he
scheduling derails of each processing steps. The
Operation Gantt Chart for the conplet€ recipe of a
single batch operation is shown in Fig. 2. It should
also be noted that the process time for certain
operations arc dependant upon other op€rations of
otber procedure (e.g. Transfer-out fiDction in P-4 is
sel equal to the filling duration of P-5). Hence, th€
dwation of this slave operation is set to follow to the
duration of the master operation using the Master-
Slave Relationship tunction of SuperPro Designer
(Intellisen, 2003).
The customer denand for this anri-allergic crean
product is expected to rhe anothet 150% of the
current production capaciq in coming y€ats.
However, the Focess is currently running at its
marjmum capadty and any anempl of increasing
production is not Possible due to the process
boitleneck. This calls for a systematic procedure to
analyse the curent producdon facilities and next, to
debottleneck the process.




From the base case simulatioq a complete batch of
pharmaceutical cream production has a process batch
time of 40.2 hrs and a minimum cycle tiine of 29 hrs-
The minimum cyole tine of the prooess ets the plant
anoual Foduction at 66 baLh€s, widr 11,333 tubes of
anti-allergic cream produced per batch. The oapacity,
tirne and combined utilisation of all the
procedure/equipment pairs in th€ base cas€
simulation. As shown in Fig. 3, the Main Blendirg
ProcedurE P-4 (V-103) has the highest cornbined
utilisation of all prooedures. The product of
equipment utilisarion and uptine leads to the highest
oombined utilisation of 84.1% for P-4lV-103, and
heroe ;t is identified as the overall process bottleneck
After id€ irying the Main Blending Procedure P-4
(V-103) as the process bottleneck, debottlenecking
strategies will nexr be focused on reducing €;ther the
size or time utilisation ofthis procedure/equipment
Fig. 3. Capac;ty, time and co'nbined utilhation for
unit prooedures in base case simulation.
5, DEBOTTLENECKING SCHEMES
After identifying the candidate for process
debodlenecting. rhe feasibiliD of various
d€bottlene.king schemes were evaluated lsing
superPro Designer. Four debottlerecking schenes
werc matysed in which all schemes were upplied
focusing on reducing the equipment uptinre of P-4,^r'-
I 03 as the process time bottlereck.
For debottlenecking Schene l, a new intermediat€
tank V-104 is installed after the Main Blending
vessel. fie TransfeFout opemlion in P-4lV 
- 
I 03 is no
longer crnstrajned by rhe slow filling operation in
Filler P-5FL-101. Upon the completion on the
blending operations in P-4,^r'-103, the Foduct
mixiure is transfened into the newly added V-104 for
t€mporary storage, while waiting for the filling
operation to complete. Simulation results showed
ftat rhe annual production for $is scheme is
determined as 87 batches, wi$ rhe rcduction of
minimum cycl€ time that limits the nurnber of annual
production from 29 hrs (in the base case simularion)
to 21.6 hrs. This conesponds roan increase ofannual
production rate of 32%, but is insufficient to tulfil
projected cuitomer demands.
Schem€ 2 focuses on ihe reduction of cooling
operation of P-4,^r'-103 instead. A mulriftnctional
blerding tank with a cooling systeDr (purchase cost of
LSD 255.000) is installed to replace tle main
blending tank. This reduces the cooling tirne of the
product mixture fton th€ cunent 19 hours to 5 hours.
Chilled water is us€d as cooling agent to cool tbe
mixlure from 85'C to room temperature. This leads
to the reduction of rnininum cycle time lo 15 hrs.
Hence, sn increase of 83.3ol" is achieved for annual
production as conpared to the base case, i.e. fiom 66
to 121 batches. How€v€r, P-4fr'-103 remains as the
ovenll process bottleneck although its combired
utilisation valu€ bas be€n reduc€d from the ourrent
84.2To to 79.3o/o (as the uptime was reduced from
94"/' to 88o/o). Further deboftlenecking can only be
achieved if the long durarion of ils Transfer-out
operation (to filler P-5,GL-101) can be rcduoed.
Scheme 3 explored the reduction of P-4lv-103
uptime fiom a different perspective wh€re a new filler
(50 tubes/min; purchase cost of USD 300,000) is
installed in addiiion to the new multifunctional
blending lank in Scheme 2 to acc€lerate the filling
rate. AD annual p.odoction of 147 batches with a
minimum cycle time of 12 hrs is achi€ved.
Simulation result! showed that altlough the duration
of Tnnsfer-oul operation in P4/V-103 can be
reduc€d significadly, dre combined utilisation value
of P-4,ry-103 is only ieduced slightly to 77.10%o
(*on 793avo) in Schene 2). Th€ resultins annuat
production is determined as 147 batches, i.e. an
ADother debottlerecking altemativ€ focusing on
reducin8 the overall uptime ofP-4/V-103 is presenied
ir Soheme 4 (Fig. 4). Instead of installi.g a new
filling machine a! in Scheme 3, an intermediate
storage tsnl( (v-104; plrrchase crst of usD10,000) is
added here in addition to fte installation of a new
Bl€nding Tank (P-4,^/-103) Sinulatiot resuh,
showed thar the annual produclion ior !his scheme i<
173 batches lvith a mjnimum cycle time reduoed 1o
9.9 hts. Ttis co esponds to an inc.ease of annual
production rate of 162%, fulfilling the fthrre market
Fig. 4. Debottlenetking Scheme 4
installatiori of intermediate tank
multitunctioml blending tank.
It should also be noted that after tbe installation of
intermediate storage tank P-10^r'-101, the nai,
blending tank (P-4,^/-103) is no longer the process
bottleneck. Thh is consistent witb the finding of
Koulouris e/ al (2000), where new bofileneck
equipment will emerge after the current bottleneck is
overcome. Debotttenecking efons are stopped atthis
scheme as the debotdenecking objective is reached,
i.e. achieving the 150% increase in produotion as
compared to curent Production
6. CONCLUSION
In this worlq cornputeFaided Proc€ss design (CAPD)
- and sirnulation tools ate used in the syst€matic
identification of th€ process bottleneck and a
debottlenecking study. A local phannaceutical case
study of anti-allergic cream productior is used io
demonstraie the effectiveness of th€ tools. The base
oase ard four debottleneckng schemes are simulated
using SuperPro Desiger. lt is shown that wjtll tbe
reduction of equipment uptime of the Focess time
botdeneck, the annual prooess ihroughpd is increased
significantly. The study resulted in a debotdenecking
scherne that achieves the cunent produotion ne€ds.
and
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